Orexigen has completed the reacquisition of the US rights to Contrave from Takeda, putting it in control of its own destiny as it is no longer depending on a partner. However, with this opportunity comes quite a bit of risk as operating expenses will balloon to $200m per year over the next few years, more than double the previous level thanks to the need to hire an internal salesforce of 160. These increased expenses are the main reason we are lowering our valuation from $14.70 to $4.80 per s
19 Aug 2016
In control of its own destiny
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In control of its own destiny
- Published:
19 Aug 2016 -
Author:
Maxim Jacobs -
Pages:
7
Orexigen has completed the reacquisition of the US rights to Contrave from Takeda, putting it in control of its own destiny as it is no longer depending on a partner. However, with this opportunity comes quite a bit of risk as operating expenses will balloon to $200m per year over the next few years, more than double the previous level thanks to the need to hire an internal salesforce of 160. These increased expenses are the main reason we are lowering our valuation from $14.70 to $4.80 per s